NCT00255918View on ClinicalTrials.gov

Investigation of the Drug Dimethoxbenzylidene Anabaseine in Treating Schizophrenia Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

October 31, 2005

Study Completion Date

October 31, 2005

Conditions
SchizophreniaPsychotic Disorders
Interventions
DRUG

Dimethoxybenzylidene anabaseine (DMXB-A)

DMXB-A 150 mg immediate release followed by DMXB-A 75 mg 2 hours after the intiial dose

DRUG

Placebo

Placebo dosed to match active medication

DRUG

Dimethoxybenzylidene anabaseine (DMXB-A)

DMXB-A 75 mg immediate release followed by DMXB-A 37.5 mg 2 hours after the intiial dose

Trial Locations (1)

80262

University of Colorado General Clinical Research Center, Denver

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

University of Colorado, Denver

OTHER

NCT00255918 - Investigation of the Drug Dimethoxbenzylidene Anabaseine in Treating Schizophrenia Patients | Biotech Hunter | Biotech Hunter